-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 31, Junshi Biological issued an announcement stating that the company received the "Notice of Drug Clinical Trial Approval" approved and issued by the National Medical Products Administration, and the clinical trial application of JS014 injection for the treatment of advanced malignant tumors was approved
The active ingredient of JS014 injection is recombinant interleukin 21-anti-human serum albumin (HSA) nanobody fusion protein.
In June 2019, the company signed a "License Agreement" with Anwita Biosciences, Inc.